Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEM301 in Advanced Metastatic Colorectal Cancer
NCT07805369Phase 1Recruiting
- Sponsor
- DEM BioPharma
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of DEM301 in colorectal cancer (CRC) (2 arms), sponsored by DEM BioPharma. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days, Incidence of Adverse Events up to 24 months and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
DEM301
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07805369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07805369.